DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Lang I, Brodowicz T, Ryvo L. et al.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lancet Oncol 2013;
14: 125-133
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.